On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.

Wilson Sonsini Goodrich & Rosati advised Stately Bio on the transaction. The team that advised Stately Bio included Ken Clark, Lance Brady, Norm Hovijitra, Alison Sechrest, Maya Prasad, and Kexi Wang.

For more information, please see Stately Bio’s press release. Additional coverage can be found on Endpoints.